Available online on 15.06.2026 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research



Open Access

Review Article

# Emerging Innovations in Pharmaceutical Drug Delivery and Formulation Technologies: Current Advances, Clinical Relevance and Future Perspectives

**Amar M. Raval[1]*, Fayeja M. Zankhwala[2], Pratiksha C Chandragirivar[3], Rakesh S A[4]**

[1]Associate Professor, Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India

[2]Assistant Professor, Department of Pharmaceutics, Shree Swaminarayan Institute of Pharmacy, Tajpur, Gujarat, India

[3]Assistant Professor, Department of Pharmaceutics, GM Institute of Pharmaceutical Sciences and Research, Davanagere, Karnataka, India

[4]Assistant Professor, Department of Pharmacognosy, GM Institute of Pharmaceutical Sciences and Research, Davanagere, Karnataka, India

## A B S T R A C T

Pharmaceutical sciences have undergone remarkable transformation over the past decade due to advances in formulation development, excipient engineering, nanotechnology, analytical techniques, digital healthcare, and regulatory sciences. The increasing prevalence of chronic diseases, antimicrobial resistance, patient-specific therapeutic requirements, and demand for improved healthcare outcomes has accelerated innovation in pharmaceutical technology. Traditional dosage forms often face limitations such as poor aqueous solubility, inadequate bioavailability, instability, limited permeability, and poor patient adherence. These limitations have encouraged the development of advanced oral delivery systems, transdermal formulations, nanotechnology-based carriers, and multifunctional excipient platforms.

Recent pharmaceutical innovation has focused on improving therapeutic effectiveness while simplifying administration and enhancing patient convenience. Fast dissolving tablets, gastro-retentive systems, solid dispersions, microneedles, vesicular delivery systems, and nanocrystal formulations have demonstrated substantial clinical and industrial relevance. Simultaneously, advances in analytical method development and validation have improved product quality, regulatory compliance, and stability assessment. Artificial intelligence has emerged as a transformative tool in pharmaceutical research and healthcare practice, contributing to drug discovery, precision medicine, and digital pharmacovigilance. In parallel, growing attention to pharmacovigilance and materiovigilance has strengthened post-marketing safety monitoring and regulatory decision-making.

This review comprehensively discusses recent innovations in pharmaceutical drug delivery and formulation technologies, including oral delivery systems, excipient engineering, transdermal technologies, nanotechnology, analytical science, digital transformation, safety monitoring, and future pharmaceutical trends. Emphasis is placed on clinical applicability, translational significance, and future opportunities in patient-centered pharmaceutical care.

**Keywords:** Pharmaceutical technology, co-processed excipients, transdermal delivery, fast dissolving tablets, nanotechnology, artificial intelligence, pharmacovigilance

**A R T I C L E I N F O:** Received 18 Nov. 2025; Review Complete 21 Feb, 2026; Accepted 27 March. 2026; Available online 15 June. 2026

**Cite this article as:**

Raval AM, Zankhwala FM, Chandragirivar PC, Rakesh S A, Emerging Innovations in Pharmaceutical Drug Delivery and Formulation Technologies: Current Advances, Clinical Relevance and Future Perspectives, Asian Journal of Pharmaceutical Research and Development. 2026; 14(3):-309-315, DOI: http://dx.doi.org/10.22270/ajprd.v14i3.1795

*Address for Correspondence:

Amar M. Raval, Associate Professor, Department of Pharmaceutics, Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India

## INTRODUCTION

Pharmaceutical formulation science has undergone remarkable advancement over the last two decades, driven by the increasing complexity of therapeutic molecules, evolving patient expectations, and growing global healthcare demands.

The pharmaceutical industry is no longer focused solely on developing therapeutically active compounds; modern drug development requires integration of formulation science, delivery technology, patient compliance strategies, regulatory expectations, and manufacturing scalability. The goal of pharmaceutical formulation is not only to deliver the drug effectively but also to ensure stability, therapeutic precision, safety, convenience, and consistent clinical outcomes [1-5].

Traditional dosage forms such as tablets, capsules, suspensions, and ointments continue to dominate pharmaceutical markets because of established manufacturing processes and patient familiarity. However, many active pharmaceutical ingredients (APIs) possess inherent limitations including poor aqueous solubility, inadequate permeability, and instability in biological environments, short biological half-life, extensive first-pass metabolism, and poor patient acceptability. These limitations reduce therapeutic effectiveness and often demand formulation innovations capable of overcoming physicochemical and biological barriers [6].

A major challenge in contemporary pharmaceutical sciences is the increasing number of poorly soluble molecules entering development pipelines. Many newly discovered APIs belong to Biopharmaceutical Classification System (BCS) class II and IV categories, where solubility and permeability issues significantly limit oral bioavailability. Conventional formulations often fail to provide adequate therapeutic plasma concentration, leading to delayed onset of action, dose escalation, or poor clinical response [7-10]. To address these concerns, advanced formulation technologies such as solid dispersions, nanocrystals, lipid carriers, microneedles, gastro-retentive systems, and controlled-release platforms are increasingly used [11].

Patient-centered healthcare has also transformed formulation design. Pediatric and geriatric populations require dosage forms that are easier to administer and improve adherence. Fast dissolving tablets, orally disintegrating films, transdermal patches, and wearable delivery systems are increasingly preferred because they reduce administration difficulty and enhance convenience. Improved adherence directly influences treatment success, especially in chronic disease management [12].

In addition to dosage form innovations, pharmaceutical sciences have expanded into interdisciplinary domains such as artificial intelligence, digital therapeutics, predictive analytics, pharmacovigilance, and automated manufacturing systems. Artificial intelligence is increasingly applied for drug discovery, molecular screening, formulation optimization, predictive stability assessment, and personalized medicine. Pharmacovigilance and materiovigilance systems contribute significantly to post-marketing safety monitoring and patient protection [13-17].

The integration of pharmaceutical engineering, computational tools, regulatory science, and patient-focused innovation has significantly transformed formulation development. These innovations are improving therapeutic effectiveness, reducing adverse reactions, increasing manufacturing efficiency, and supporting precision healthcare delivery [18].

This review comprehensively summarizes recent innovations in pharmaceutical drug delivery and formulation science with emphasis on oral delivery technologies, multifunctional excipient systems, transdermal and nanotechnology-based platforms, analytical advancements, artificial intelligence applications, and future industrial perspectives [19].

**Table 1:** Major Challenges Driving Innovation in Pharmaceutical Formulation

| Challenge | Impact on Therapy | Innovative Formulation Approach | Example |
|---|---|---|---|
| Poor aqueous solubility | Reduced absorption | Solid dispersion / nanocrystals | Ranolazine |
| Low permeability | Poor bioavailability | Lipid carriers / permeation enhancers | Peptides |
| First-pass metabolism | Reduced systemic availability | Transdermal systems | Diclofenac |
| Frequent dosing | Low compliance | Sustained-release tablets | Metformin XR |
| Swallowing difficulty | Poor adherence | Fast dissolving tablets | Ondansetron ODT |
| Drug instability | Degradation | Encapsulation / polymer coating | Omeprazole |
| Variable GI residence | Inconsistent absorption | Gastro-retentive systems | Ciprofloxacin |
| Patient preference | Compliance issues | Oral thin films / wearable systems | Pediatric formulations |

## Advanced Oral Drug Delivery Systems

Oral administration remains the most widely preferred route because of convenience, affordability, and patient acceptability. Despite these advantages, the gastrointestinal tract presents multiple barriers including pH variation, enzymatic degradation, motility, food interactions, and limited absorption windows. Advanced oral delivery systems are designed to overcome these limitations and improve pharmacokinetic performance [20].

### Fast Dissolving Tablets

Fast dissolving tablets disintegrate rapidly upon contact with saliva without requiring water. These formulations are especially beneficial for pediatric, geriatric, psychiatric, and bedridden patients experiencing dysphagia.

The development of FDTs depends on balancing mechanical strength with rapid disintegration. Excess hardness may delay disintegration, whereas excessive porosity may compromise stability. Modern formulation approaches use co-processed excipients and optimized superdisintegrants to improve both structural integrity and rapid dispersion [21].

Common superdisintegrants include:

- Crospovidone
- Croscarmellose sodium
- Sodium starch glycolate
- Ion-exchange resins

Advantages include rapid onset, improved patient compliance, better acceptability, reduced choking risk, and convenience during emergency therapy.

**Table 2:** Detailed Comparison of Advanced Oral Delivery Systems

| Technology | Mechanism | Advantages | Limitations | Example |
|---|---|---|---|---|
| Fast dissolving tablets | Rapid saliva disintegration | Compliance | Moisture sensitivity | Ondansetron |
| Solid dispersion | API dispersed in polymer | Dissolution enhancement | Stability concern | Ranolazine |
| Gastro-retentive tablets | Gastric retention | Extended release | Food dependence | Metformin |
| Oral thin film | Buccal dissolution | Rapid action | Dose limitation | Cetirizine |
| Multiparticulate systems | Multiple mini units | Uniform release | Processing complexity | Omeprazole pellets |

## Co-Processed Excipients and Multifunctional Pharmaceutical Platforms

Excipients are fundamental components of pharmaceutical formulations and significantly influence manufacturing performance, dosage form stability, drug release, and therapeutic acceptability. Traditionally, excipients such as binders, diluents, lubricants, disintegrants, and glidants were incorporated individually to achieve specific functions. However, modern pharmaceutical development increasingly demands excipients capable of performing multiple functions simultaneously while maintaining process efficiency and formulation reproducibility.

Co-processed excipients represent an important advancement in pharmaceutical technology. These systems involve combining two or more excipients through physical modification techniques such as spray drying, granulation, melt extrusion, or solvent evaporation without causing chemical interaction. The resulting material exhibits superior functionality compared with simple physical mixtures because of improved particle architecture and synergistic performance [22].

The importance of co-processed excipients has increased significantly with the expansion of direct compression manufacturing and fast-dissolving technologies. Pharmaceutical manufacturers seek excipient systems with excellent flowability, compressibility, uniform distribution, reduced segregation, and reliable tablet hardness. Co-processed excipients improve these characteristics and reduce process complexity [23].

These systems also support improved industrial scalability. Reduced number of individual excipient additions minimizes weighing error, simplifies inventory management, shortens processing time, and improves batch-to-batch consistency. Such benefits are particularly valuable in high-speed tablet manufacturing [24].

Co-processed excipients are extensively used in:

- Fast dissolving tablets
- Direct compression tablets
- Sustained-release matrix systems
- Bilayer tablets
- Nutraceutical formulations
- Pediatric dosage forms
- Combination therapy products

The future of excipient engineering may include customized patient-specific excipient platforms, AI-assisted excipient selection, and multifunctional polymer composites capable of combining release control with stability enhancement.

**Table 3:** Co-Processed Excipients and Pharmaceutical Benefits

| Co-processed excipient | Components | Major function | Pharmaceutical advantage | Application |
|---|---|---|---|---|
| Microcrystalline cellulose + lactose | Diluent/compression | Flow + hardness | Direct compression | Tablets |
| Crospovidone blends | Disintegration | Rapid breakup | FDTs | Pediatric tablets |
| Starch + cellulose | Binding/disintegration | Uniform compression | Faster processing | Oral solids |
| Mannitol + superdisintegrant | Mouthfeel/disintegration | Palatability | ODT | Geriatric |
| Polymer combinations | Controlled release | Sustained release | Extended therapy | Matrix tablets |

## Transdermal and Topical Drug Delivery Systems

Transdermal and topical delivery systems have become increasingly important because they provide therapeutic effectiveness while minimizing gastrointestinal degradation and avoiding hepatic first-pass metabolism. These systems improve patient adherence, maintain controlled plasma concentration, and reduce dosing frequency [25-28].

The skin is a complex barrier, primarily due to the stratum corneum. Drug delivery through skin therefore requires optimized formulation strategies involving permeation enhancement, carrier systems, polymer engineering, and controlled-release design.

## Polymer-Based Transdermal Patches

Transdermal patches consist of:

- Drug reservoir
- Polymer matrix
- Adhesive layer

- Backing membrane
- Protective liner

They provide controlled drug release over extended periods and maintain stable therapeutic levels.

### Advantages:

- Avoid first-pass metabolism
- Reduced dosing frequency
- Better compliance
- Lower GI irritation
- Improved plasma consistency

### Microneedle Drug Delivery

Microneedles are micro-scale projections that create temporary channels through the stratum corneum without pain [29-32].

### Types:

- Solid microneedles
- Hollow microneedles
- Dissolving microneedles
- Coated microneedles

### Major advantages:

- Painless administration
- Minimal invasiveness
- Improved biologic delivery
- Self-administration
- Reduced infection risk

### Microneedles are especially promising for:

- Vaccines
- Insulin
- Peptides
- Biologics

### Ethosomal Systems

Ethosomes are phospholipid vesicles containing ethanol that improve flexibility and skin permeation [33-40].

Applications include:

- Anti-inflammatory agents
- Cosmetic products
- Antifungal therapy
- Herbal topical systems.

**Table 4:** Comparative Analysis of Transdermal Systems

| System | Mechanism | Major advantage | Limitation | Example |
|---|---|---|---|---|
| Patch | Controlled diffusion | Sustained delivery | Skin irritation | Diclofenac |
| Microneedles | Microchannels | Painless | Cost | Vaccine |
| Ethosomes | Enhanced penetration | Better absorption | Stability | Herbal gel |
| Creams/ointments | Surface absorption | Easy use | Variable penetration | Wound care |

### Nanotechnology and Quality by Design

Nanotechnology has become one of the most transformative tools in pharmaceutical science. Reduction of drug particle size into nanometer range significantly alters dissolution behavior, surface area, and absorption characteristics.

Major nanotechnology approaches include:

- Nanocrystals
- Liposomes
- Nanoemulsions
- Polymeric nanoparticles
- Lipid nanoparticles

### Advantages:

- Increased dissolution
- Better absorption
- Improved bioavailability
- Targeted delivery
- Lower dose requirement
- Reduced toxicity

Quality by Design (QbD) complements nanotechnology by ensuring systematic development through risk assessment and optimization [41].

QbD elements:

- Quality target product profile
- Critical quality attributes
- Design of experiments
- Risk analysis
- Process control

This integration improves reproducibility and regulatory acceptance.

**Table 5:** Nanotechnology-Based Drug Delivery

| Drug | Technology | Benefit | Clinical value |
|---|---|---|---|
| Trazodone | Nanocrystals | Faster dissolution | Better onset |
| Ranolazine | Solid dispersion | Improved bioavailability | Cardiac therapy |
| Fenoprofen | PEG dispersion | Sustained release | Pain management |
| Curcumin | Nanoparticles | Increased absorption | Anti-inflammatory |

### Pharmaceutical Analytical Science and Regulatory Quality

Analytical science is essential for ensuring pharmaceutical quality and regulatory compliance.

Primary objectives include [42]

- Assay accuracy
- Impurity profiling
- Stability monitoring
- Process validation
- Batch release
- Regulatory documentation

Modern methods:

- HPLC
- RP-HPLC
- HPTLC
- UV spectroscopy
- Dissolution profiling
- Forced degradation studies

Analytical science supports:

- ICH compliance
- Shelf-life determination
- Manufacturing consistency
- Quality assurance

**Table 6:** Analytical Methods in Pharmaceutical Development

| Method | Purpose | Application |
|---|---|---|
| HPLC | Assay | API estimation |
| RP-HPLC | Stability | Impurity profiling |
| HPTLC | Simultaneous analysis | Combination products |
| UV spectroscopy | Routine QC | Fast screening |
| Dissolution test | Release profile | Tablet evaluation |

## Artificial Intelligence in Pharmacy [43]

Artificial intelligence is revolutionizing pharmaceutical sciences by integrating data-driven decision making.

Applications include:

### Drug Discovery

- Molecular screening
- Target identification
- Lead optimization

### Formulation Development

- Excipient prediction
- Stability forecasting
- Optimization

### Clinical Pharmacy

- Personalized medicine
- Dose adjustment
- ADR prediction

### Pharmacovigilance

- Safety signal detection
- Pattern analysis

### Manufacturing

- Predictive maintenance
- Process monitoring
- Supply chain planning

AI reduces development time and improves precision.

**Table 7:** AI Applications in Pharmaceutical Science

| Area | Application | Benefit |
|---|---|---|
| Discovery | Screening | Faster development |
| Formulation | Prediction | Better optimization |
| Clinical pharmacy | Personalization | Improved care |
| Manufacturing | Analytics | Efficiency |
| Pharmacovigilance | ADR monitoring | Safety |

## Pharmacovigilance and Materiovigilance[44]

Drug and device safety remain central to healthcare systems.

Pharmacovigilance includes:

- ADR reporting
- Signal detection
- Risk evaluation
- Safety communication

Materiovigilance monitors:

- Medical device failure
- Defects
- Adverse device incidents

These systems protect patients and improve regulatory oversight.

**Table 8:** Safety Monitoring Systems

| System | Focus | Benefit |
|---|---|---|
| Pharmacovigilance | Drug safety | ADR control |
| Materiovigilance | Device safety | Risk prevention |
| Post-marketing surveillance | Long-term monitoring | Better compliance |

## Clinical Therapeutic Impact[45]

### Innovative drug delivery influences management of:

- Hypertension
- Diabetes
- PCOS

- Antibiotic resistance
- CNS disorders
- Chronic pain

### Clinical outcomes improved through:

- Better adherence
- Faster onset
- Sustained therapy
- Lower adverse effects

**Table 9:** Therapeutic Relevance

| Disease | Innovation | Benefit |
|---|---|---|
| Diabetes | Controlled release | Better glucose control |
| Hypertension | Sustained tablets | Compliance |
| PCOS | Personalized dosing | Improved outcomes |
| Infection | Rapid release | Faster response |

### Future Perspectives[46]

Future pharmaceutical innovation is expected to focus on:

- Personalized medicine
- 3D printed dosage forms
- Wearable delivery systems
- AI-guided development
- Smart sensors
- Digital therapeutics
- Sustainable manufacturing
- Green chemistry

The pharmaceutical industry is moving toward highly individualized, technology-driven therapeutic care.

## CONCLUSION

Pharmaceutical sciences continue to evolve rapidly through integration of advanced formulation science, multifunctional excipient engineering, nanotechnology, transdermal delivery, analytical innovation, artificial intelligence, and pharmacovigilance.

These advancements significantly improve:

- Therapeutic Effectiveness
- Patient Adherence
- Safety
- Manufacturing Efficiency
- Regulatory Quality

Modern pharmaceutical care increasingly depends on interdisciplinary collaboration between formulation scientists, clinicians, engineers, data scientists, and regulatory professionals.

Future pharmaceutical development will likely be defined by precision medicine, intelligent manufacturing, patient-centered delivery systems, and digital healthcare integration, ultimately improving both clinical outcomes and global healthcare quality.

## REFERENCES


1. Gattu K, Kim Y, Lee S. Microneedle technologies for drug delivery: recent advances, fabrication strategies and clinical applications. *Pharmaceutics.* 2026;18(2):215-238.
2. Zhang Z, Liu H, Chen P, Wang Y. Enhancing transdermal drug delivery with dissolving microneedles: formulation design and therapeutic applications. *J Control Release.*2026;356:240-258.
3. Herdiana Y, Rahman M, Wijaya T. Artificial intelligence as a disruptive force in pharmaceutical sciences: recent advances and future directions. *Pharmaceutics.* 2026;18(4):488-512.
4. Mevada J, Patel K, Raval AM. Materiovigilance: From device failure to safety reform, the growing importance of materiovigilance systems. Int J Pharm Sci. 2026;4(1):962-74.
5. Falwariya, R., Jethva, T., Raval, A.M. and Lokhande, D., 2026. Comprehensive review: Microneedle patches-A painless revolution in transdermal drug delivery. *World J Pharm Med Res*, *12*(1), pp.199-207.
6. Singh S, Kumar R, Patel A. A comprehensive review of artificial intelligence in drug delivery and formulation optimization. *Pharm Med.* 2026;40(3):145-166.
7. Raval AM, Patel PB, Patel H. Artificial intelligence in pharmacy and healthcare: opportunities and implementation challenges. *Asian J Pharm Res Dev.* 2026;14(2):84-97.
8. Melo MEOC, Santos F, Lima R. Amorphous solid dispersions as a strategy to enhance oral bioavailability of poorly water-soluble compounds. *Pharmaceutics.* 2026;18(3):376-398.
9. Mevada J, Patel K, Raval AM. Role of pharmacovigilance in drug safety monitoring. World J Pharm Med Res. 2025;11(11):235-40.
10. Rathi S. Physicochemical Characterization and In-Vitro Dissolution Enhancement of Ranolazine Using Solid Dispersion Method. Available at SSRN 3507970. 2019 Dec 21.
11. Raval AM, Bhavsar PR, Pandya FU, Patel D. Co-processed excipients in pharmaceutical formulation: advances, characterization, and applications. Asian Journal of Pharmaceutical Research and Development. 2026 Feb 16;14(01):105-13.
12. Patel N, Raval AM. Gastro-retentive drug delivery system: A review. Int J Pharm Sci. 2026;4(1):734-42.
13. Raje V, Kulkarni A, Sharma P. Development of amorphous solid dispersion of delamanid using hot-melt extrusion for oral bioavailability enhancement. *Int J Pharm.*2026;647:124138.
14. Daravath B, Mehta R, Kumar N. QbD-driven solid dispersion development for enhanced solubility and dissolution of poorly soluble drugs. *Pharmaceutics.* 2026;18(5):603-621.
15. Stantsov MI, Krasnyuk II, Bokov DO. The effect of solid dispersions on solubility and therapeutic performance of poorly soluble drugs. *Res J Pharm Technol.* 2026;19(3):1401-1410.
16. Gupta R, Rawat A, Sethi T. Dissolution enhancement of poorly soluble drugs using solid dispersion technique: a review. *Int J Adv Chem Res.* 2026;8(1):184-191.
17. World Health Organization. Pharmacovigilance: regulation and safety of medicines. Geneva: WHO; 2026.
18. Indian Pharmacopoeia Commission. Materiovigilance Programme of India: annual medical device safety monitoring report. Ghaziabad: IPC; 2026.
19. Indian Pharmacopoeia Commission. National pharmacovigilance programme annual report 2026. Ghaziabad: IPC; 2026.
20. Sharma D, Verma K, Patel S. Advances in co-processed excipients for fast dissolving tablet development and industrial scale-up. *Int J Pharm Sci Rev Res.* 2026;76(1):90-106.
21. Lee H, Park J, Kim Y. Multifunctional excipient platforms for direct compression: pharmaceutical and manufacturing perspectives. *Drug Dev Ind Pharm.* 2026;52(4):410-426.
22. Zankhwala MF, Raval MA, Kushkiwala MA, Sarvaiya MS, Raval MK, Thakar MN, Barjod MS. Formulation And Evaluation Of Optimized Polymer Blends For Diclofenac Diethylamine Transdermal System. The Review of Diabetic Studies. 2025 Sep 14:701-8.
23. Kushkiwala AM, Zankhwala FM, Patel MD, Raval AM. Flurbiprofen loaded ethosomal gel: Design, optimization, and anti-inflammatory activity. Int J Res Anal Rev. 2024;11(4):709-42.

24. Raval MA, Suthar MA, Durani MB, Thakar MN, Zankhwala MF, Kushkiwala MA, Rathod MS. Smart Co-Processed Excipient Platforms: A Novel Strategy for Multifunctional Optimization of Ibuprofen Tablet Formulations. practice.;1:2.
25. Patel PS, Raval AM, Kumar PA, Kumar PP, Ghanshyam PT. A comprehensive review of antibiotic resistance: mechanisms, causes, and novel therapeutic approaches. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):117-28.
26. Nguyen HV, Tran D, Le M. Improved dissolution of poorly water-soluble rutin via solid dispersion and tablet optimization. *Pharmaceutics.* 2026;18(1):119-135.
27. Patel R, Shah M, Trivedi N. Recent advances in ethosomal gel formulations for dermal and transdermal drug delivery. *Int J Pharm Investig.* 2026;16(2):102-117.
28. Bala S, Pawar P, Singh A. Oral thin films in modern pharmaceutical delivery: formulation and patient compliance considerations. *Drug Dev Ind Pharm.* 2026;52(2):181-197.
29. American Diabetes Association. Standards of care in diabetes—2026. *Diabetes Care.* 2026;49(Suppl 1):S1-S312.
30. Whelton PK, Carey RM. Contemporary management of hypertension and emerging pharmaceutical treatment approaches. *Hypertension.* 2026;87(2):220-239.
31. Raval AM, Rana T, Joshi SY, Buch S, Arora B, Patel VS. Artificial intelligence in pharmacy and healthcare: applications in drug discovery, precision medicine, clinical practice, and future perspectives. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):62-9.
32. Senjaliya T, Patel M, Raval AM. Strategies for combating the global health threat of antibiotic resistance: novel therapeutics and combination approaches. Asian Journal of Pharmaceutical Research and Development. 2026 Feb 15;14(01):122-30.
33. Thakor AD, Dharajiya RM, Shaikh MZ, Raval AM. A review on neuropharmacology: mechanisms, drug classes, and clinical applications. Asian Journal of Pharmaceutical Research and Development. 2026 Feb 15;14(01):114-21.
34. kumar Patel PB, Raval AM, Patel HB, Patel KH, Poorv P, Vaidya PA, Kahar KH. A comprehensive review of polycystic ovary syndrome (PCOS): pathophysiology, diagnosis and management. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):32-41.
35. Raval AM, Maneklal RJ, Dilipbhai MU. Development and Evaluation of PolyherbalTopical Cream for Wound Healing Applications Using Alum, Turmeric, and Aloe Vera. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):234-40.
36. Raval AM, Utpalkumar PF, Utpalkumar PV, Ratnakar BP. Development and Evaluation of Multifunctional Co-Processed Excipients for Fast Dissolving Tablet Formulation. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):226-33.
37. Raval AM, Verma AR, Prajapati DS. Efficacy and Safety of Major Antihypertensive Drug Classes in Adults with Hypertension: A Systematic Review. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):216-25.
38. Panthaki J, Bhai YL, Kumar VS, Raval AM. Formulation and Evaluation of Body Scrub Using Walnut Shell Powder. Asian Journal of Pharmaceutical Research and Development. 2026 Apr 15;14(2):241-7.
39. Amar M. Raval AMR, Krina N Chaudhari KNC, Dr. Bhoomi Arora DBA, Dr. Aastha Ukani DAU, Riddhi Modh RM, Dr. Kuldeep Choubisa DKC, Dr. Ashok Kumar DAK. Emerging Role of GLP-1 and Dual Incretin Agonists in the Management of Type 2 Diabetes Mellitus: Mechanisms, Clinical Evidence, Dosing Strategies, and Future Perspectives. International Journal of Medical and Pharmaceutical Research. 2026 May;7(3):357-370.
40. Upadhyay J, Yadav P, Patel D, Raval A, Patel J. Review on in-situ depot-based controlled drug delivery for treatment of rheumatoid arthritis treatment. World Journal of Pharmaceutical and Medical Research. 2025 Nov;11(11):113-117. doi:10.5281/zenodo.17483326
41. Goswami V, Shukla R, Patel B, Suthar A, Patel P, Raval AM. HPTLC method development and validation for simultaneous estimation of rifaximin and metronidazole benzoate in combined tablet dosage form. Int J Drug Deliv Technol. 2026;16(46s):257-265. doi:10.25258/ijddt.16.46s.27.
42. Kumar PA, Mohmmed N, Chandragirivar PC, Raval AM. Design space exploration of trazodone nanocrystals via DOE: formulation and in vitro-in vivo assessment. Int J Drug Deliv Technol. 2026;16(42s):1358-1368. doi:10.25258/ijddt.16.42s.146.
43. Chandragirivar PC, Banu A, Raval AM, Kusuma R, Srinidhi G, Yashwanth HB, Suheel A. Improved dissolution performance of fenoprofen calcium using PEG 6000 solid dispersions: preparation by fusion method and physicochemical characterization. Int J Drug Deliv Technol. 2026;16(36s):771-781. doi:10.25258/ijddt.16.36s.87.
44. Joshi SY, Detholia KK, Raval AM, Dharu NR, Rathod SR, Kushkiwala AM. Development and validation of a stability-indicating RP-HPLC method for quantitative estimation of sunitinib malate in pharmaceutical dosage form. Int J Drug Deliv Technol. 2026;16(12s):418-426. doi:10.25258/ijddt.16.12s.48.
45. Bhatt R, Raval AM, Patel J, Patel D. Oral thin film drug delivery systems for thrombosis therapy: a comprehensive review. Int J Pharm Sci. 2026;4(1):3563-3576. doi:10.5281/zenodo.18423515.
46. Prajapati A, Yadav P, Raval AM, Patel J. Review on solid dispersion-based fast dissolving tablets: formulation approaches and evaluation. World J Pharm Med Res. 2025;11(11):109-112. doi:10.5281/zenodo.17483241